Jayanta Dowaraha,
Devanshi Patelb,
Brilliant N. Maraka,
Umesh Chand Singh Yadavc,
Pramod Kumar Shahd,
Pradeep Kumar Shuklad and
Ved Prakash Singh*ae
aDepartment of Chemistry, School of Physical Sciences, Mizoram University, Aizawl-796004, Mizoram, India. E-mail: vpsingh@mzu.edu.in
bSchool of Life Sciences, Central University of Gujarat, Gandhinagar, Gujarat 382030, India
cSpecial Centre for Molecular Medicine, Jawaharlal Nehru University, New Delhi-110067, India
dDepartment of Physics, Assam University, Silchar-788011, India
eDepartment of Industrial Chemistry, School of Physical Sciences, Mizoram University, Aizawl-796004, Mizoram, India
First published on 4th November 2021
In this study, for the first time, we have used Citrus macroptera juice to synthesize dihydropyrimidine (DHPM) derivatives via the Biginelli reaction, which showed better yield, shorter reaction time, and did not require an organic solvent for the reaction. A series of DHPM derivatives were synthesized, and characterized, and structural analysis was achieved through SCXRD & Hirshfeld surface analysis. We observed that these synthesized dihydropyrimidine (DHPM) derivatives showed C–H⋯π, C–H⋯O, C–H⋯N, C–H⋯C, lone pair⋯π, π⋯π, etc. interactions. We also performed in silico studies for their inhibitory activities against human kinesin Eg5 enzyme, and the cytotoxic activity of the synthesized compounds was carried out against A549 lung adenocarcinoma cells. In silico analysis demonstrated that compounds with a chloro-group at the 3- or 4-position in the substituted ring of DHPM showed higher binding affinity for the human kinesin Eg5 enzyme (−7.9 kcal mol−1) than the standard drug monastrol (−7.8 kcal mol−1). Furthermore, in vitro cellular studies revealed that compounds with a chloro-group at the 3- or 4-position in the substituted ring of DHPM induced significant cell death in human A549 lung adenocarcinoma cells. This result indicates that a deactivating group (chlorine) at the 3- or 4-position in the substituted ring of DHPM might be a promising anticancer drug candidate for treating different types of cancers, particularly cancer of the lung.
Heterocyclic molecules continue to be attractive targets for synthesis since they often exhibit vital biological properties. In particular, dihydropyrimidinones (DHPMs) are well known for their wide range of bioactivities. DHPMs have vital applications in the field of drug discovery. Three nucleic acid bases are pyrimidine derivatives, which comprise cytosine, found in DNA and RNA, uracil in RNA, and thymine in DNA (Fig. 1). Therefore, the synthesis and study of DHPM systems with methylene-linked ester makes it an exciting topic for synthetic organic chemistry.
DHPM classes of compounds are structural analogs of monastrol. These are important to medicinal chemistry because of many biological activities.4 These compounds also possess interesting biological activities such as antiviral,5 antitumor,6 and antibacterial,7 as well as calcium channel modulating activity.8 Monastrol is the protagonist of the DHPMs class. Several studies revealed that DHPMs inhibitory action on human kinesin Eg5 leads to a mitotic arrest resulting in apoptosis.9 This was the main action in apoptosis described for this class of compounds. However, some studies have shown other possible targets, such as centrin,10 calcium channels,11 and topoisomerase I12 for these molecules. Monastrol has inspired medicinal chemists to design new anticancer agents based on the DHPM scaffold or its modification with different substituents. Broad replacements (R1, R2, R3, R4, and X) were set on various ring places, meaning to get vital anticancer specialists, for example, dimethylenastron, compounds 1, 2, and 3 (Fig. 2). Thus, we have designed our synthetic compounds based on these structural attributes of monastrol.
The present study deals with the green synthesis of monastral analogues and studies weak interactions, including π⋯π interactions, C–H⋯π and lone pair⋯π interactions. Our first effort was to understand non-covalent interactions in the synthesized DHPM derivatives and the effect of substituents with different electronic environments on conformations of some selected synthesized molecules.
The synthesis of DHPM and evaluation of their anticancer properties is of ongoing interest to our laboratory. Synthesis of DHPM derivatives by “solvent-free and catalyst-free” green methodology has been done by others.13 Pramanik et al. developed a safe, eco-friendly, and green method for synthesizing DHPM at room temperature using common fruit juice.14 Microwave-assisted green synthesis of DHPM was developed by Bhatewara et al. and studied their antimicrobial properties.15 Citrus macroptera (a fruit from citrus family, usually found in India, Bangladesh, Malaysia and Melanesia) juice medium never have been used for Biginelli reaction using electron-rich/electron-deficient aromatic aldehydes, but similar kind of citrus fruit like orange and lime has been reported earlier for similar reactions.14 Here, we have reported a green synthesis for DHPM with electron-rich and electron-deficient aromatic aldehydes in Citrus macroptera juice medium [Scheme 1]. The non-covalent interactions of these compounds were studied by single-crystal X-ray diffractometers (SCXRD). Hirshfeld surface analyses were performed to study the structural property of molecules. DFT calculations were carried out to know how the substituents impact the geometry of different synthesized DHPM derivatives. In silico analysis studies the molecules binding affinity in the active site of target proteins (Eg5). Subsequently, we also carried out cytotoxic studies of these compounds in the lung adenocarcinoma (A549) cells.
δH (300 MHz; CDCl3; Me4Si): 1.11–1.15 (3H, t, CH3, J = 7.2 Hz), 2.11–2.16 (3H, s, CH3), 4.15–4.18 (2H, q, CH3, J = 7.2 Hz), 5.29–5.37 (1H, s, CH), 7.22–7.35 (5H, s, Ph), 9.21–9.24 (1H, s, NH), 9.87–9.91(1H, s, NH). δC (75MHz; CDCl3): 14.2, 18.3, 58.6, 61.7, 104.2, 126.3, 126.9, 128.5, 143.3, 160.3, 167.2, 174.1. MS (m/z): 277.09 (M+). Element analysis: found: C, 60.64; H, 5.46; N, 10.33%. Calculated for C14H16N2O2S: C, 60.85; H, 5.84; N, 10.14%.
δH (300 MHz; CDCl3; Me4Si): 1.12–1.16 (3H, t, CH3, J = 7.2 Hz), 2.31–2.39 (3H, s, CH3), 4.1–4.13 (2H, q, CH2, J = 7.2 Hz), 5.28–5.33 (1H, s, CH); 7.21–7.32 (4H, s, Ph), 9.27–9.34 (1H, s, NH), 9.88–9.95 (1H, s, NH). δC (75MHz; CDCl3): 14.2, 18.3, 58.6, 61.7, 104.2, 126.9, 128.5, 132.3, 143.3, 160.3, 167.2, 174.1. MS (m/z): 311.05 (M+). Element analysis: found: C, 54.21; H, 4.53; N, 9.12%. Calculated for C14H15ClN2O2S: C, 54.10; H, 4.86; N, 9.01%.
δH (300 MHz; CDCl3; Me4Si): 1.11–1.23 (3H, t, CH3, J = 7.2 Hz), 2.32–2.39 (3H, s, CH3), 3.74–3.79 (3H, s, OCH3), 4.11–4.13 (2H, q, CH2, J = 8.4 Hz), 5.31–5.35 (1H, s, CH), 6.78–6.86 (2H, d, Ph, J = 8.4 Hz), 7.16–7.23 (2H, d, Ph, J = 8.4 Hz), 7.8–7.84 (1H, s, NH), 8.43–8.51 (1H, s, NH). δC (75MHz; CDCl3): 14.2, 18.3, 55.8, 58.3, 61.7, 104.2, 114.1, 125.7, 135.6, 158.6, 160.3, 167.2, 174.1. MS (m/z):307.10 (M+). Element analysis: found: C, 58.60; H, 5.84; N, 9.06%. Calculated for C15H18N2O3S: C, 58.80; H, 5.92; N, 9.14%.
δH (300 MHz; CDCl3; Me4Si): 1.12–1.23 (3H, t, CH3, J = 7.2 Hz), 2.26–2.32 (3H, s, CH3), 2.33–2.38 (3H, s, CH3), 4.1–4.13 (2H, q, CH2, J = 7.2 Hz), 5.28–5.33 (1H, s, CH), 7.08–7.12 (2H, d, Ph, J = 8.2 Hz) 7.14–7.23 (2H, d, Ph, J = 8.1 Hz), 8.81–8.86(1H, s, NH), 9.48–9.52 (1H, s, NH). δC (75 MHz; CDCl3): 14.2, 18.3, 21.3, 58.3, 61.7, 104.2, 126.8, 128.8, 136.4, 140.3, 160.3, 167.2, 174.1. MS (m/z): 291.11 (M+). Element analysis: found: C, 62.21; H, 6.11; N, 9.38%. Calculated for C15H18N2O2S: C, 62.04; H, 6.25; N, 9.65%.
δH (300 MHz; CDCl3; Me4Si): 1.13–1.21 (3H, t, CH3, J = 7.2 Hz), 2.24–2.37 (3H, s, CH3), 4.1–4.13 (2H, q, CH2, J = 7.2 Hz), 5.27–5.31 (1H, s, CH), 7.18–7.31 (4H, m, Ph), 9.37–9.44 (1H, s, NH), 9.98–10.03 (1H, s, NH). δC (75 MHz; CDCl3): 14.2, 18.3, 57.8, 61.7, 104.2, 125.0, 126.7, 126.8, 129.9, 134.1, 144.7, 160.3, 167.2, 174.1. MS (m/z): 311.05 (M+). Element analysis: found: C, 54.04; H, 4.45; N, 9.21%. Calculated for C14H15ClN2O2S: C, 54.10; H, 4.86; N, 9.01%.
Fig. 3 ORTEP diagram of ellipsoids at 50% probability level with the atomic numbering scheme for: (A) 1.3, (B) 1.4, and (C) 1.5. |
Crystal data | 1.3 | 1.4 | 1.5 |
---|---|---|---|
Identification code | 1936021 | 1936022 | 1936023 |
Empirical formula | C15H18N2O3S | C15H18N2O2S | C14H15N2O2SCl |
Formula weight | 306.39 | 290.39 | 310.81 |
Temperature (K) | 296 (2) | 296 (2) | 296 (2) |
Crystal system | Monoclinic | Triclinic | Triclinic |
Space group | C2/c | P | P |
a (Å) | 18.2332 (17) | 7.3603 (10) | 7.3066 (6) |
b (Å) | 7.3341 (6) | 9.4648 (12) | 10.4657 (8) |
c (Å) | 25.197 (2) | 12.2076 (16) | 10.6788 (9) |
α (°) | 90 | 74.216 (4) | 107.568 (3) |
β (°) | 101.888 (4) | 88.729 (4) | 90.538 (3) |
γ (°) | 90 | 69.819 (4) | 107.829 (2) |
Volume (Å3) | 3297.2 (5) | 765.70 (18) | 736.37 (10) |
Z | 8 | 2 | 2 |
ρ (g cm−3) | 1.2343 | 1.2594 | 1.4016 |
μ (mm−1) | 0.207 | 0.214 | 0.403 |
F (000) | 1297.5879 | 308.3750 | 324.6689 |
Crystal size (mm3) | 0.24 × 0.22 × 0.22 | 0.22 × 0.20 × 0.18 | 0.26 × 0.25 × 0.20 |
Radiation | Mo Kα (λ = 0.71073) | Mo Kα (λ = 0.71073) | Mo Kα (λ = 0.71073) |
2Θ range for data collection (°) | 2.28 to 28.37 | 2.96 to 2715 | 3.38 to 27.16 |
Reflections collected | 39480 | 18180 | 14725 |
Independent reflections | 4117 | 3387 | 3263 |
Data/restraints/parameters | 4117/0/201 | 3387/0/192 | 3263/0/191 |
Goodness-of-fit on F2 | 1.0714 | 1.0675 | 1.0760 |
Final R indexes [I ≥ 2σ (I)] | R1 = 0.0636, wR2 = 0.1885 | R1 = 0.0423, wR2 = 0.1218 | R1 = 0.0384, wR2 = 0.1104 |
Final R indexes [all data] | R1 = 0.0764, wR2 = 0.2033 | R1 = 0.0487, wR2 = 0.1298 | R1 = 0.0429, wR2 = 0.1156 |
Largest diff. peak/hole/e Å−3 | 0.57/−0.43 | 0.34/−0.38 | 0.28/−0.43 |
In the crystal structure of compound 1.3, the crystal packing is stabilized by dimers through N–H⋯S hydrogen bonds in a R22 (8) ring motif (Fig. 4). One more intermolecular hydrogen bonding of N–H⋯O & C–H⋯O results in the generation of a dimeric structure, which can be described as R12 (6) graph-set notation in which thioamide & ester oxygen are involved (Fig. 4B). The hydrogen-bonding network for compound 1.3 and crystal packing are given in Fig. 4. Compound 1.3 exhibits a stacked arrangement of molecules. They exhibit a combination of parallel-displaced C–H⋯π, C–H⋯O, N–H⋯O, and N–H⋯S interactions (Table 2). D is the donor, and A is the acceptor in non-covalent interactions in Table 2. Both rings are arranged in an ABBA pattern in crystal packing. The acute angle between the plane of the non-aromatic ring and phenyl ring is 87.68°. The stacking distances for C–H⋯π were 2.669, 2.925, and 3.376 Å (Table 2 and Fig. 4C). The N–H⋯O and N–H⋯S bond distances for hydrogen bonding were 2.184, 2.463 Å, and angles on hydrogen atoms were 169.84°, 172.54°. Apart from these interactions, the C–H⋯O interactions also assist the interlayer connectivity and linear chain formation. The C–H⋯O bond distances for hydrogen bonding were 2.716, 2.770, 2.918 & 2.953 Å, and angles on hydrogen atoms were 132.54°, 137.19°, 119.22, and 118.79°, respectively (Table 2 & Fig. 4).
D–H⋯A | D–H (Å) | H⋯A (Å) | D⋯A (Å) | D–H⋯A (°) | Symmetry operation |
---|---|---|---|---|---|
Compound 1.3 | |||||
C1–H1c⋯Oaa | 0.959 | 2.770 | 3.534 | 137.19 | 1.5 − x, −1/2 + y, 1.5 − z |
N4–H4⋯S1 | 0.862 | 2.463 | 3.316 | 169.84 | 1.5 − x, 1/2 − y, 1 − z |
C3–H3a⋯O1 | 0.930 | 2.918 | 3.468 | 119.22 | 1.5 − x, −1/2 + y, 1.5 − z |
C4–H4a⋯O1 | 0.930 | 2.953 | 3.497 | 118.79 | 1.5 − x, −1/2 + y, 1.5 − z |
C15–H15c⋯O0aa | 0.960 | 2.716 | 3.439 | 132.54 | x, −1 + y, z |
N3–H3⋯O0aa | 0.804 | 2.184 | 2.983 | 172.54 | x, −1 + y, z |
C10–H10a⋯S1 | 0.961 | 3.251 | 4.001 | 137.89 | −1/2 + x, 1/2 + y, z |
C14–H14⋯S1 | 0.930 | 3.144 | 3.875 | 136.92 | x, −1 + y, z |
C6–H6⋯S1 | 0.980 | 3.182 | 4.095 | 155.77 | x, −1 + y, z |
C1–H1a⋯π (C2, C3, C4, C5, C13, C14) | 0.960 | 3.627 | 3.684 | 1.5 − x, −1/2 + y, 1.5 − z | |
C1–H1b⋯π (C5, C4, C2, C3, C13, C14) | 0.961 | 2.925 | 3.684 | 1.5 − x, −1/2 + y, 1.5 − z | |
C10–H10c⋯π (C5, C4, C2, C3, C13, C14) | 0.959 | 2.699 | 3.641 | −1/2 + x, 1/2 + y, z | |
Intramolecular | |||||
C3–H3a⋯O1 | 0.930 | 2.644 | 2.443 | ||
C13–H13a⋯O1 | 0.930 | 2.492 | 2.341 | ||
C9–H9a⋯O0aa | 0.970 | 2.588 | 2.675 | ||
C9–H9b⋯O0aa | 0.970 | 2.736 | 2.675 | ||
C15–H15c⋯N3–H3 | 0.960 | 2.125 | 2.394 | ||
Compound 1.4 | |||||
C12–H12c⋯Oaa | 0.960 | 2.713 | 3.403 | 129.33 | −1 + x, y, z |
C4–H4⋯S1 | 0.930 | 3.063 | 3.731 | 130.12 | −1 + x, y, z |
C6–H6⋯S1 | 0.980 | 3.268 | 4.146 | 150.03 | −1 + x, y, z |
N3–H3⋯S1 | 0.889 | 2.450 | 3.322 | 166.91 | 1 − x, −y, −z |
N2–H2⋯O0aa | 0.810 | 2.257 | 3.058 | 170.02 | −1 + x, y, z |
C12–H12a⋯Oaa | 0.960 | 2.713 | 3.403 | 129.33 | −1 + x, y, z |
Intramolecular | |||||
C15–H15⋯π (C6, C7, C11, C13, N2, N3) | 0.931 | 2.846 | 3.067 | ||
C12–H12a⋯O1 | 0.960 | 2.914 | 2.800 | ||
C12–H12b⋯O1 | 0.960 | 2.317 | 2.800 | 110.40 | |
C6–H6⋯O0aa | 0.980 | 2.474 | 2.812 | ||
C9–H9a⋯O0aa | 0.970 | 2.546 | 2.686 | ||
Compound 1.5 | |||||
C1–H1⋯O0aa | 0.980 | 2.747 | 3.684 | 159.68 | −1 + x, y, z |
C12–H12a⋯O0aa | 0.960 | 3.456 | 3.390 | 119.22 | −1 + x, y, z |
C12–H12c⋯O0aa | 0.960 | 2.705 | 3.390 | 128.86 | −1 + x, y, z |
N3–H3⋯O0aa | 0.805 | 2.186 | 2.981 | 189.86 | −1 + x, y, z |
C8–H8a⋯Cl2 | 0.970 | 2.952 | 3.767 | 142.39 | −x, 1 −y, 1 − z |
N2–H2⋯S1 | 0.829 | 2.584 | 3.401 | 188.89 | 1 − x, 1 − y, 2 − z |
C5–H5⋯S1 | 0.980 | 3.213 | 4.126 | 155.57 | −1 + x, y, z |
C8–H8b⋯S1 | 0.970 | 3.098 | 4.024 | 160.25 | 1 − x, 2 − y, 2 − z |
C9–H9a⋯S1 | 0.960 | 3.385 | 4.211 | 145.54 | 1 − x, 2 − y, 2 − z |
C14–H14⋯S1 | 0.980 | 3.060 | 3.888 | 149.30 | 1 − x, 2 − y, 2 − z |
C9–H9c⋯π (C1, C2, C3, C4, C13, C14) | 0.959 | 3.180 | 4.128 | x, −1 + y, z | |
C2–H2a⋯π (C2, C1, C13, C14, C4, C3) | 0.930 | 3.611 | 3.874 | −x, 1 − y, 1 − z | |
C1–H1⋯π (C1, C2, C3, C4, C13, C14) | 0.930 | 3.480 | 3.369 | −x, 1 − y, 1 − z | |
(C1, C2, C3, C4, C13, C14) π⋯π (C3, C4, C14, C13, C1, C2) | 3.665 | −x, 1 − y, 1 − z | |||
Intramolecular | |||||
C5–H5a⋯O0aa | 0.980 | 2.449 | 2.786 | ||
C8–H8a⋯O0aa | 0.970 | 2.578 | 2.670 | ||
C8–H8b⋯O0aa | 0.970 | 2.732 | 2.670 | ||
C12–H12a⋯O1 | 0.960 | 2.881 | 2.786 | ||
C12–H12b⋯O1 | 0.960 | 2.309 | 2.786 |
The overall structure of 1.4 exhibits a combination of C–H⋯O, N–H⋯O, and N–H⋯S interactions (Table 2). Phenyl rings are arranged in a hairbone pattern in crystal packing. The acute angle between the plane of the non-aromatic ring and phenyl ring is 80.95°. Dimers also stabilize the crystal packing of compound 1.4 through N–H⋯O, N–H⋯S, & C–H⋯O hydrogen bonds in R12 (6), R22 (8), and R44 (20) ring motif, where thioamide & ester oxygen are involved (Fig. 5A and B). The hydrogen-bonding network for compound 1.4 and crystal packing are shown in Fig. 5. In addition to intermolecular C–H⋯O interactions compound, 1.4 also showed intra-molecular C–H⋯O interactions. The N–H⋯O and N–H⋯S bond distances for hydrogen bonding were 2.257, 2.450 Å, and angles on hydrogen atoms were 170.02°, 166.91°, respectively. The C–H⋯O bond distance and angle on hydrogen atom were 2.713 Å and 129.33°, respectively (Table 2 and Fig. 5). An intramolecular C–H⋯π interactions (H15⋯Cg = 2.846 Å) were also observed, which further stabilized interlayer connectivity of crystal structure.
Crystal structure of 1.5 exhibits a combination of parallel-displaced C–H⋯π, C–H⋯O, N–H⋯O, and N–H⋯S interactions (Table 2). Both rings are arranged in the AABB pattern in crystal packing. The acute angle (dihedral angle) between the non-aromatic ring and phenyl ring plane is 80.18°. Crystal 1.5 also stabilized like the rest two crystals by the dimers through N–H⋯S, N–H⋯O & C–H⋯O non-traditional hydrogen bonds resulting in the R12 (6), R22 (8), and R44 (20) graph-set notation (Fig. 6). For crystal structure of 1.5, one π⋯π stacking interaction was also observed, and distance for π⋯π stacking interaction was 3.665 Å (Fig. 6B). The stacking distances for C–H⋯π were 3.180, 3.611, 3.480 Å (Table 2), which further assisted the interlayer connectivity and linear chain formation of crystal structure. The N–H⋯O and N–H⋯S bond distances for hydrogen bonding were 2.1876, 2.584 Å, and angles on hydrogen atoms were 138.86°, 168.69°, respectively (Table 2 and Fig. 6). The C–H⋯O bond distance for R12 (6) ring motif is 2.705 Å and angles on hydrogen atoms was 128.86°, while the other C–H⋯O bond distance were 2.747, 3.456 Å and angle on hydrogen atom were 159.68 and 119.28°, respectively (Table 2).
Fig. 7 (A) Two-dimensional fingerprint plot for compound 1.3, (B) non-covalent interactions forming R22 (8) ring motif. |
Fig. 8 (A) Two-dimensional fingerprint plot for compound 1.4, (B) non-covalent interactions forming R22 (8) ring motif. |
Fig. 9 (A) Two-dimensional fingerprint plot for compound 1.5, (B) non-covalent interactions forming R22 (8) ring motif. |
Donor–H⋯acceptor | D–H, Å | H⋯A, Å | D⋯A, Å | D–H⋯A, o | Symmetry operation |
---|---|---|---|---|---|
Compound 1.3 | |||||
N3–H3⋯O0aa | 1.205 | 1.981 | 2.983 | 171.78 | x, y, z |
N4–H4⋯S1 | 1.009 | 2.319 | 3.316 | 169.20 | −x + 1/2, −y + 1/2, −z |
C3–H3a⋯C2 | 1.083 | 2.725 | 3.581 | 142.65 | −x + 1/2, y + 1/2, −z + 1/2 |
Compound 1.4 | |||||
N2–H2⋯O0aa | 1.009 | 2.061 | 3.058 | 169.06 | x, y, z |
N3–H3⋯S1 | 1.009 | 2.334 | 3.322 | 166.24 | −x, −y, −z |
C9–H9b⋯S1 | 1.083 | 2.993 | 4.046 | 164.18 | −x, −y, −z |
Compound 1.5 | |||||
C1–H1⋯O0aa | 1.083 | 2.604 | 3.634 | 158.51 | −x, −y, −z |
N3–H3⋯O0aa | 0.504 | 2.981 | 4.189 | 168.82 | x, y, z |
C9–H9c⋯C13 | 1.083 | 2.728 | 3.754 | 158.08 | x, y, z |
C9–H9c⋯C14 | 1.083 | 2.750 | 3.797 | 162.65 | x, y, z |
N2–H2⋯S1 | 0.504 | 2.408 | 3.401 | 167.85 | −x, −y, −z |
C8–H8b⋯C10 | 1.083 | 2.676 | 3.672 | 152.66 | −x, −y, −z |
Spoke-like pattern in the fingerprint plots of 1.3, 1.4 and 1.5 represents C–H⋯O interactions in crystal lattice in region of di + de = 2.00–3.0 Å, with H⋯O/O⋯H contributions of 12.4%, 6.9% and 7.7%, respectively (Fig. 7A, 8A and 9A). The second spoke-like pattern in the fingerprint plots of 1.3, 1.4 and 1.5 represents C–H⋯S interactions in crystal lattice in region of di + de = 2.30–3.4 Å with H⋯S/S⋯H contributions of 15.1%, 15.5% and 16.7%, respectively (Fig. 7A, 8A and 9A). The C–H⋯π interactions in compounds 1.3, 1.4 and 1.5 can be seen as a pair of unique blue-colored wings in the region of di + de = 3.2–3.6 Å with H⋯C/C⋯H contribution of 15.2%, 14.2% and 12.9%, respectively (Fig. 7A, 8A and 9A). The C–H⋯N pair of contacts is also reflected as two characteristic wings occupied in di + de = 3.2–3.5 Å in compounds 1.3, 1.4, and 1.5. The yellowish-red bin is absent on the fingerprint plots in compounds 1.3 and 1.4, which means the absence of weak π⋯π stacking in crystal packing (Fig. 7A and 8A. However, there is a light yellowish-red bin (with C⋯C contact of contribution is 3.9%) present on the fingerprint plot indicates the existence of weak π⋯π stacking interactions between the phenyl rings in compound 1.5 (Fig. 9A). The Hirshfeld weak interactions calculation found a similar weak non-covalent intermolecular interactions pattern in crystal packing. C–H⋯π interactions, C–H⋯N, and C–H⋯O interactions, etc., of compound 1.3, 1.4 and 1.5 in crystal packing structure are in Fig. 7B, 8B, 9B) and Table 3. In all three crystal structure's, 1.3, 1.4, and 1.5, extensive hydrogen-bonding network of calculated interactions, terminal carbonyl oxygen, thio-pyrimidine nitrogen, and thio-pyrimidine sulfur are involved in weak interaction and forming eight membered R22 (8) (Fig. 7B, 8B and 9B) rings.
The role of π⋯π stacking is central importance in chemistry as well as bio medicine field. They are key interactions influencing the tertiary structure of proteins, the vertical base stacking in DNA, and the intercalation of different drugs into DNA, which helps in drug design. The role of π⋯π stacking also become prominent in drug–receptor interactions as most of the drugs are aromatic, and about 20% of amino acids are aromatic. The curvedness plots and shape index plots of 3D Hirshfeld is a very promising tool to visualize π⋯π stacking interactions in the crystals.34 In curvedness plots, the yellow spots represent very weak intermolecular interactions, and red-yellow colored spots represent strong hydrogen-bonding interactions in the crystal structures of 1.3, 1.4, and 1.5 (Fig. 10). In curvedness plots of compounds 1.3 and 1.4, the absence of green-colored flat regions bounded by red-colored rectangles on the phenyl rings further confirms the non-existence of π⋯π stacking effect in crystal packing (Fig. 10A & C). However, in the curvedness plots of compound 1.5, flat green colored regions bounded by red-colored rectangles on phenyl rings, once again confirm the presence of π⋯π stacking effect in crystal packing of 1.5 (Fig. 10E). Red and blue regions represent the acceptor and the donor property, respectively, in the shape index of compound 1.3, 1.4, and 1.5 (Fig. 10B, D & F). Yellowish-red colored concave regions inside the counters indicate the presence of weak intermolecular interactions in the Shape index plots of compounds 1.3, 1.4, and 1.5 (Fig. 10B and D).The absence of adjacent red and blue triangles in the shape-index map of 1.3 and 1.4 also proved the lack of π⋯π stacking effect in the crystal packing (Fig. 10B and D). There are adjacent red and blue triangles bounded by the black colored rectangles in the shape-index map of 1.5, once again confirms the π⋯π stacking effect in the crystal packing of 1.5 (Fig. 10F).
Fig. 11 Potential energy surfaces for twisting the phenyl rings in the synthesized DHPM derivatives (1.3, 1.4, 1.5) as obtained at the M06-2X/6-31+G(d,p) level of theory. |
We note from Fig. 11 that each PES is characterized by only one minimum and the fully planar configurations (0° and 180°) are unstable. The DHPM derivatives with torsion angle (∼40°) are found to be energetically most unstable. The global minimum for 1.3, 1.4 and 1.5 molecule are found to be at torsion angle of 155.5°, 146.8° and 152.3°, respectively (Fig. 11), which is in agreement with their crystal structure. The optimized geometries of 1.3, 1.4 and 1.5 are shown in Fig. S5 (ESI†). Thus, our DFT calculations show that substituents do not impact the geometry of synthesized DHPM derivatives appreciably.
We also calculated the interaction energies of DHPM derivatives (1.3, 1.4 and 1.5) with their neighbouring molecules in the crystal structure at the M06-2X/6-31+G(d,p) level of theory. We considered neighbouring molecules which are in direct contact with a central molecule for complex formation and thus complexes formed by 8, 5 and 7 molecules for 1.3, 1.4 and 1.5, respectively, were taken for calculation of interaction energy. These complexes are shown in Fig. S7 and S8 (ESI†). The interaction energy of a complex was calculated as follows:
Interaction energy = total energy of the complex − n × total energy of one molecule |
The interaction energies of the complexes of 1.3, 1.4 and 1.5 are found to be −103.20, −24.61, −90.81 kcal mol−1, respectively. The interaction energy per molecule for 1.3, 1.4 and 1.5 are −12.90, −6.15 and −12.97 kcal mol−1, respectively. This indicates that 1.4 has very less tendency to associate with other molecule as compared to 1.3 and 1.5 molecule.
The common trend in the binding interactions of compounds 1.2, 1.5, and 1 (monastrol) in the cavity of Eg5 is observed. Ester group protrudes outside the cavity of Eg5. In silico analysis revealed that compounds 1.2 and 1.5 showed better binding energy (−7.9 kcal mol−1) than the standard drug monastrol (−7.8 kcal mol−1) (Table 4). Chlorobenzene ring of compounds 1.2 and 1.5 is directed towards the hydrophobic region of the active site of Eg5 (Fig. 12A and B). The chlorobenzene ring of 1.2 and 1.5 are orientated towards the hydrophobic region, so π-anion interactions with the negatively charged residue Glu116 will be favorable. Compound 1.5 also showed one halogen bond with the residue Trp127, which indicated that compound 1.5 fits nicely into the cavity of Eg5. Further, the residues Ala 133, Pro137, and Tyr211, Leu214, and Arg221 facilitate the hydrophobic π-alkyl and alkyl interactions with compound 1.5 (Fig. 12B) and (Table 4).
Compounds | Docking score (kcal mol−1) | Residues involved in H-bond | Residues involved in other interactions (π-anion, π–σ, π–π, π-alkyl, and alkyl) |
---|---|---|---|
1.1 | −7.8 | Glu116 | Ala 133, Pro 137 |
1.2 | −7.9 | Glu116 | Leu160, Ile136, Leu214, Arg221, Phe239 |
1.3 | −7.1 | Glu116 | Glu116, Arg119, Leu214, Ala218 |
1.4 | −7.7 | Glu116 | Glu116, Ile136, Leu214, Phe239 |
1.5 | −7.9 | Glu116, Trp127 (halogen bond) | Ala 133, Pro137, Tyr211, Leu214, Arg221 |
1 (monastrol) | −7.8 | Glu116, Glu118 | Arg119, Ala133, Pro137, Leu214, Ala218 |
Fig. 12 (A) and (B) Binding mode of compounds 1.2 and 1.5 in the active site cavity of Eg5 protein, respectively. |
Fig. 16 A549 adenocarcinoma cells were treated with 200 μM 1.2 and 1.5 compounds for 24 and 48 h and stained with Hoechst stain. Representative images are shown (n = 3) at 200× magnification. |
It has been observed that DHPM exists as a dimer as found in all 1.3, 1.4, and 1.5 crystal structures. Our results through the single crystal and Hirshfeld analysis found the existence of the dimeric structure of DHPM. The two such monomers lead to the dimer by forming an additional hydrogen bond yielding the bifurcated hydrogen bonds and N–H–S bridges. The presence of the thioamide group in the series exists in monomer–dimeric equilibrium. The two monomers lead to the dimer by forming by N–H–S hydrogen bond.
In addition to the N–H–S hydrogen bond (Figs. 4, 5, and 6), two more intermolecular hydrogen bonding interactions C–H⋯O, N–H⋯O are observed between the oxygen atom of the ester group and hydrogen atom of the thioamide group. These additional H-bonds form tetramer of DHPM. The overall structure of the tetramer is close to planar. Hydrogen bonding represents one of the most versatile interactions that could be used for molecular recognition. It might be possible to interfere with the strength of the hydrogen bond effectively by linking the hydrogen-bonding site to a binding site of the molecule with the receptor. The presence of π⋯π stacking in compound 1.5 will also help to study the drug receptor interactions of this compound.
A comparision of in vitro effects of synthesized DHPM derivatives (1.2 and 1.5) with potent anticancer agents such as monastrol, dimethylenastron, compounds 1, 2, and 3 (Fig. 2) from DHPM scaffold is shown in Table 5. Monastrol and dimethylenastron inhibit mitotic kinesin Eg5 protein, whereas compound 1 inhibit proliferation of prostate cancer cells PC3 (IC50 = 37 μM) as well as lung cancer cells NCI–H1299 (IC50 = 40 μM). Compound 2 inhibit proliferation of leukemia cell lines HL-60(TB) (IC50 = 0.05656 μM) as well as MOLT-4 (IC50 = 1.788 μM). Compound 3 also inhibit proliferation of breast cancer cell lines SK-BR-3 with GIC50 value of ±0.4 μM. Whereas, synthesized DHPM derivatives 1.2 and 1.5 significantly inhibit proliferation of lung adenocarcinoma cells A549 at 200 μM concentration.
Anticancer drugs | Target with efficiency |
---|---|
Monastrol | Inhibit mitotic kinesin Eg5 protein (IC50 = 14 μM) |
Dimethylenastron | Inhibit mitotic kinesin Eg5 protein(IC50 = 200 nM) |
Compound 1 | Inhibit proliferation of prostate cancer cells PC3 (IC50 = 37 μM), lung cancer cells NCI–H1299 (IC50 = 40 μM) |
Compound 2 | Inhibit proliferation of leukemia cell lines HL-60(TB) (IC50 = 0.05656 μM) and against MOLT-4 (IC50 = 1.788 μM) |
Compound 3 | Inhibit proliferation of breast cancer cell lines SK-BR-3 (GIC50 = ±0.4 μM) |
1.2 | Significantly inhibit proliferation of lung adenocarcinoma cells A549 at 200 μM |
1.3 | Significantly inhibit proliferation of lung adenocarcinoma cells A549 at 200 μM |
Both in silico and in vitro results also found the same order of anti-cancer activity. An in silico study showed that order of binding affinity is 1.2–1.5 > 1.1 > 1.4 > 1.3, whereas in vitro study showed that variants 1.2, 1.4, and 1.5 decreased the cell viability significantly. Analogues 1.2, 1.4, and 1.5 also induced significant cell death in A549, but 1.2 and 1.5 were found significant in this group. Both 1.2 and 1.5 treatment caused apoptosis-induced cell death in A549 cells. Nuclear fragmentation in A549 adenocarcinoma cells by Hoechst staining showed that both 1.2 and 1.5 can induce apoptosis in cells.
As shown in tables 1.4, the values of inhibition zone for ligands are related to the nature of substituent as they increase according to the following order: p-Cl ∼ m-Cl > H > p-CH3 > p-OCH3. This can be attributed to the fact that the effective charge experienced by the central ring increased due to de-activating substituent (p-Cl ∼ m-Cl). At the same time, it decreased by activating group H > p-CH3 > p-OCH3. It is important to note that existence of a methyl and/or methoxy group enhances the electron density in the ring and simultaneously decreases inhibition zone values.
Electron withdrawing bridge would be expected to increase the acidity of proton donors and hence increase its binding ability as the electron-withdrawing character of a chloro group is relevant to the best analogue 1.2 and 1.5. In general, hydrogen bonds involving OH groups are proton donors, and their O atoms are proton acceptors. Both intra and intermolecular OH–N may form several structures in simultaneous equilibrium.
The DHPM series of compounds can induce intracellular oxidation resulting in cytosolic toxicity and genome toxicity in cancer cells. These events can further cause changes at the molecular level, ultimately resulting in an altered cell cycle leading to apoptosis. These events could also reduce migration ability and impede tumor growth resulting in reduced tumor size and migration of cancer cells. These findings suggest that 1.2 and 1.5 might be potential anticancer drug candidates. Thus, these analogues can be promising agents for treating various cancers, including lung cancer.
Footnote |
† Electronic supplementary information (ESI) available. CCDC 1936021–1936023. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/d1ra03969e |
This journal is © The Royal Society of Chemistry 2021 |